anti-SPP1 neutralizing antibody

An anti-SPP1 neutralizing antibody is a biologic therapeutic agent designed to target and inhibit Secreted Phosphoprotein 1 (SPP1), also known as osteopontin (OPN). SPP1 is a multifunctional matricellular glycoprotein that is highly expressed by immune cells, particularly tumor-associated macrophages (TAMs) and mononuclear phagocytes (MPs), in inflammatory, fibrotic, and malignant microenvironments. By binding to and neutralizing extracellular SPP1, these antibodies disrupt its interaction with cell surface receptors such as CD44 and various integrins (e.g., αvβ3 and α9β1). This blockade inhibits downstream profibrotic and pro-inflammatory signaling pathways, reduces macrophage and neutrophil infiltration, and reverses immunosuppression in the tumor microenvironment. Preclinical studies have demonstrated that anti-SPP1 neutralizing antibodies can significantly attenuate intestinal fibrosis, pulmonary fibrosis, myelofibrosis, and renal ischemia-reperfusion injury, as well as enhance anti-tumor immunity in colorectal cancer and other malignancies. Clinical development of specific anti-SPP1 candidates, such as ASK8007, has been explored in rheumatoid arthritis, though development in that indication was discontinued due to a lack of robust efficacy.

Other names

OPN-neutralizing antibodyanti-OPN antibodyanti-osteopontin antibodyanti-SPP-1 antibodyanti-SPP1 antibodyanti-SPP 1 antibodyosteopontin-neutralizing antibodySPP1-neutralizing antibodySPP-1-neutralizing antibodySPP 1-neutralizing antibody